Elan joint venture
Executive Summary
Firm made an agreemtn-in-principle to form joint venture with Product Resources Internatl. for development of products utilizing Elan's PharmaZome technology and PRI's Edible Whip suspension drug delivery system. Elan said it also entered an agreement-in-principle with Chemie Linz AG for joint ventures in West Germany and France in which Elan will supply products and Chemie Linz will supply marketing forces.
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.